OncoResponse Names Singal Chief Scientific Officer, Puri VP of R&D

OncoResponse has named Anil Singhal chief scientific officer of the Houston-based cancer drug developer. He comes to the company from AbbVie (NYSE: [[ticker:ABBV]]), where he was vice president, early oncology development. OncoResponse has also appointed Kamal Puri vice president of research and development. Puri was most recently director, immunology & inflammation, at Celgene (NASDAQ: [[ticker:CELG]]). OncoResponse is preparing to start clinical trials testing its lead antibody drug, ONCR-201.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.